Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

@article{Skubitz2013TargetingCI,
  title={Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.},
  author={Amy P. N. Skubitz and Elizabeth P Taras and Kristin L. M. Boylan and Nate N. Waldron and Seunguk Oh and Angela Panoskaltsis-Mortari and Daniel A. Vallera},
  journal={Gynecologic oncology},
  year={2013},
  volume={130 3},
  pages={579-87}
}
OBJECTIVES While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of cells that can self-renew. CSC are more chemoresistant and radio-resistant than the bulk tumor cells; it is likely that CSC are responsible for relapse, the major problem in cancer treatment. CD133 has… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…